Adagene Inc. continues advancing its antibody engineering capabilities, leveraging patented SAFEbody technology and computational protein design to develop novel bispecific antibody-drug conjugates (ADCs). Despite persistent net losses and negative free cash flow, the company has shown material year-over-year reductions in operating deficits alongside steady R&D investments that underwrite its clinical pipeline progress. Its revenue recognition depends heavily on milestone-driven licensing and collaboration contracts, introducing timing variability. Capital allocation remains focused on equity-based incentives with no dividends or buybacks planned, underscoring a growth-stage biotech profile vulnerable to clinical and regulatory risks.